EBV NA protein [His] (DAG1578)

EBV [His], recombinant protein from E. coli

Product Overview
Recombinant EBV NA protein fused to His Tag at N-terminus was expressed in E. coli and purified by proprietary chromatographic technique.
Nature
Recombinant
Tag/Conjugate
His
Procedure
None
Purity
> 95% pure as determined by 10% PAGE (coomassie staining).
Buffer
PBS and 300mM Imidazole.
Preservative
None
Storage
2-8°C short term, -20°C long term
Introduction
The Epstein-Barr virus (EBV), also called Human herpes virus 4 (HHV-4), is a virus of the herpes family (which includes Herpes simplex virus and Cytomegalovirus. On infecting the B-lymphocyte, the linear virus genome circularizes and the virus subsequently persists within the cell as an episome. The virus can execute several distinct programs of gene expression which can be broadly categorized as being lytic cycle or latent cycle. The lytic cycle or productive infection results in staged expression of a host of viral proteins with the ultimate objective of producing infectious virions. Formally, this phase of infection does not inevitably lead to lysis of the host cell as EBV virions are produced by budding from the infected cell. The latent cycle (lysogenic) programs are those that do not result in production of virions. A very limited, distinct set of viral proteins are produced during latent cycle infection. These include Epstein-Barr nuclear antigen (EBNA)-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, EBNA-leader protein (EBNA-LP) and latent membrane proteins (LMP)-1, LMP-2A and LMP-2B and the Epstein-Barr encoded RNAs (EBERs).
Antigen Description
Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) is the one EBV antigen that is expressed in all EBV associated malignancies. It has long been thought to go undetected by the cell mediated immune system. However, recent studies show that EBNA1 can be presented to both CD4+ and CD8+ T cells, making it a potential new target for immunotherapy of EBV related cancers.
Keywords
EBV; Epstein-Barr virus; human herpesvirus 4; HHV-4; EBNA-1; Epstein-Barr Virus Nuclear Antigen; EBV Nuclear Antigen protein; human herpesvirus 4 Nuclear Antigen; HHV-4 Nuclear Antigen; Herpesviridae; Gammaherpesvirinae; Lymphocryptovirus; Human herpesvir

Citations


Have you cited DAG1578 in a publication? Let us know and earn a reward for your research.

Related Products


EBV [GST] (DAG1580)
EBV [GST] (DAG1581)
EBV [His] (DAG1584)

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


Epstein-Barr virus infection and genome polymorphisms on gastric remnant carcinoma: a meta-analysis

CANCER CELL INTERNATIONAL

Authors: Lu, Chao; Zhang, Hongtao; Zhou, Weihua; Wan, Xingyong; Li, Lan; Yu, Chaohui

BackgroundPrevious studies reported that Epstein-Barr virus (EBV) may play a causal role in the pathogenesis of gastric remnant carcinoma (GRC). However, there was still some controversy.MethodsArticles published until July 15, 2020, in PubMed, MEDLINE, Embase and CNKI databases were selected. According to the inclusion criteria, corresponding data of included articles were abstracted and used for statistical analysis.ResultsThirteen papers were finally enrolled, nine of which showed the result that the risk of EBV infection rate in the GRC was higher than conventional gastric carcinoma (OR=5.22, 95% CI 3.89-7.00). In addition, we found that EBV associated GRC (EBVaGRC) had higher rate of Billroth-II (OR=3.80, 95% CI 1.90-7.57), carcinoma in anastomotic site (OR=2.41, 95% CI 1.27-4.56) and diffuse type (Lauren classification) (OR=1.97, 95% CI 1.04-3.73),while sex, initial diagnosis and lymphocytic infiltration were calculated no statistical difference. By genetic polymorphism analysis, "V-val" subtype of EBNA1 (OR=21.84, 95% CI 11.92-31.76) and "C" subtype of BamHI-W1/I1 (OR=7.07, 95% CI 1.47-34.03) were observed to be highly expressed in EBVaGRC.ConclusionEBV infection rate in the GRC was higher. Further analysis showed that Billroth-II, carcinoma in anastomotic site and diffuse type (Lauren classification) were associated to EBVaGRC. Through analysis of EBV genome polymorphisms, we thought that "V-val" subtype of EBNA1 and "C" subtype of BamHI-W1/I1 may become predictor of EBVaGRC.

Composite EBV-negative marginal zone lymphoma and angioimmunoblastic T-cell lymphoma presenting as multiple subcutaneous nodules

EUROPEAN JOURNAL OF DERMATOLOGY

Authors: Miyagawa, Fumi; Nakajima, Anna; Ogawa, Kohei; Takeda, Maiko; Nakamine, Hirokazu; Amano, Itsuto; Asada, Hideo

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket